Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
5 October 2026
Herbert Smith Freehills Kramer advises Birch Grove in Chapter 11 liquidating plan for FreshRealm
Herbert Smith Freehills Kramer (HSF Kramer) secured a significant result on behalf of FreshRealm’s first-lien lender and DIP agent, Birch Grove.After a …
2 October 2026
Herbert Smith Freehills Kramer advises Foresight on Kondinin Wind Farm
Leading global law firm Herbert Smith Freehills Kramer (HSF Kramer) has advised Foresight, a leading global infrastructure and real assets investment …
1 October 2026
Herbert Smith Freehills Kramer hires life sciences regulatory partner Marie Manley in London
Leading global law firm Herbert Smith Freehills Kramer (HSF Kramer) has hired Marie Manley, as a partner and Head of Life Sciences Regulatory, in London.